As of June 30, 2026, InnoCare Pharma Ltd. carries a market capitalization of 52.93B, placing it among publicly traded companies globally. Its enterprise value stands at 45.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 52.93B |
| Enterprise Value | 45.50B |
InnoCare Pharma Ltd.'s next confirmed earnings release is scheduled for April 1, 2027.
| Earnings Date | 4/1/2027 |
As of June 30, 2026, InnoCare Pharma Ltd. has 4.46B shares outstanding.
| Shares Outstanding | 4.46B |
These figures are as of June 30, 2026.
| PB Ratio | 5.97 |
| P/TBV Ratio | 5.99 |
As of June 30, 2026, InnoCare Pharma Ltd. maintains a current ratio of 4.19, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.19 |
| Quick Ratio | 3.80 |
| Debt / Equity | 24.73 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 1,259.00 |
As of the close on November 17, 2026, InnoCare Pharma Ltd.'s stock has declined approximately 25.02% over the past 52 weeks. The 50-day moving average sits at 13.08, while the 200-day moving average is 13.02.
| 52-Week Price Change | -25.02% |
| 50-Day Moving Average | 13.08 |
| 200-Day Moving Average | 13.02 |
As of June 30, 2026, InnoCare Pharma Ltd. holds 9.65B in cash and equivalents against 2.20B in total debt, resulting in a net debt position of -5.13B. Total book value stands at 8.87B, with working capital of 8.10B providing operational flexibility.
| Cash & Cash Equivalents | 9.65B |
| Total Debt | 2.20B |
| Net Debt | -5.13B |
| Equity (Book Value) | 8.87B |
| Book Value Per Share | 1.99 |
| Working Capital | 8.10B |
Already premium?